Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.71 |
| ▸ | MMP9 | P14780 | 7/20 | 0.71 |
| ▸ | MMP13 | P45452 | 6/20 | 0.71 |
| ▸ | MMP1 | P03956 | 5/20 | 0.54 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6296122 | 0.76 | MMP2 (0.86) | MMP2MMP9MMP13MMP1CAPN1 | |
| SCHEMBL6291476 | 0.75 | MMP2 (0.77) | MMP2MMP9MMP13MMP1CAPN1 | |
| SCHEMBL6291475 | 0.75 | MMP2 (0.77) | MMP2MMP9MMP13MMP1CAPN1 | |
| SCHEMBL6292544 | 0.74 | MMP2 (1.00) | MMP2MMP9MMP13MMP1ADAM17 | |
| SCHEMBL6296107 | 0.70 | MMP2 (0.72) | MMP2MMP9MMP13MMP1CAPN1 | |
| SCHEMBL6296108 | 0.70 | MMP2 (0.72) | MMP2MMP9MMP13MMP1CAPN1 | |
| SCHEMBL6292540 | 0.69 | MMP2 (0.73) | MMP2MMP9MMP13MMP1CAPN1 | |
| SCHEMBL6296092 | 0.67 | MMP1 (1.00) | MMP2MMP9MMP13MMP1CAPN1 | |
| SCHEMBL288851 | 0.66 | CAPN1 (1.00) | MMP2MMP9MMP13MMP1CAPN1 | |
| SCHEMBL289202 | 0.66 | CAPN1 (1.00) | MMP2MMP9MMP13MMP1CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927216-B2 | Cyclic sulfonyl compounds as inhibitors of metalloproteases | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-08-09 | — | — | US | claimed |